Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola Post published:February 10, 2026 Post category:Interviews/Pα+
Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine in Focus; Definium Sued by Former Vendor; Psychedelics Feature in Epstein Files Post published:February 6, 2026 Post category:Psychedelic Bulletin/Pα+
Q3 2025: Oregon Psilocybin Services Update Post published:February 2, 2026 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers Post published:January 22, 2026 Post category:Psychedelic Bulletin/Pα+
Psychedelic Funding, Public Markets, and M&A in 2025 Post published:January 20, 2026 Post category:2025 Year in Review/Analysis/Pα+
Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions Post published:January 15, 2026 Post category:2025 Year in Review/Analysis/News/Pα+
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus Post published:January 8, 2026 Post category:Psychedelic Bulletin/Pα+
2025 Year in Review: Future(s) & Open Questions (Video) Post published:January 6, 2026 Post category:2025 Year in Review/Analysis/News/Pα+